Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Micrus Endovascular Corporation (“Micrus Endovascular” or the “Company”) (NASDAQ:MEND) related to the Company’s agreement to be acquired by Johnson & Johnson. The proposed cash transaction is valued at approximately $480 million.

Under the terms of the definitive agreement entered into by the parties, Micrus Endovascular shareholders will receive at closing $23.40 in cash for each Micrus share they own. Micrus shares traded as high as $22.29 as recently as July 9, 2010. The transaction is expected to close in the second half of 2010. The investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the proposed transaction by Micrus Endovascular’s board of directors.

If you own shares of Micrus Endovascular, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

Grafico Azioni Micrus Endovascular (MM) (NASDAQ:MEND)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di Micrus Endovascular (MM)
Grafico Azioni Micrus Endovascular (MM) (NASDAQ:MEND)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di Micrus Endovascular (MM)